Proposed ranibizumab biosimilar shows promise for neovascula
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
This multicenter, randomized, double-masked, parallel-group study compared intravitreous injection of SB11 with ranibizumab (0.5 mg) dosed every 4 weeks through week 48. The study cohort consisted of 705 participants aged 50 years or older diagnosed with neovascular AMD with active subfoveal choroidal neovascularization lesions.

At week 4, central subfield thickness decreased by 108 m in the SB11 group compared with 100 m in the ranibizumab group. By week 8, the change in BCVA from baseline was 6.2 letters in the SB11 group and 7 letters in the ranibizumab group. Incidences of treatment-emergent adverse events—including serious events and those leading to study drug discontinuation—were similar in both groups.

The primary shortcoming of this study is the relatively short reporting window (24 weeks). Data from longer studies are required to demonstrate continued similarities in efficacy and safety.

This study showed similar short-term efficacy and safety between SB11 and ranibizumab for neovascular AMD, contributing to the evidence supporting biosimilarity.

Read more : https://www.aao.org/editors-choice/proposed-ranibizumab-biosimilar-shows-promise-neov
Like
Comment
Share